Clinical and biological characteristics of the studied population
| Characteristics . | Patients (n = 100) . |
|---|---|
| Demographic and clinical | |
| Age (y) | 46.0 ± 12.5 |
| Male, n (%) | 48 (48) |
| Body mass index (kg/m2) | 24.1 ± 4.3 |
| Systolic blood pressure (mmHg) | 131 ± 17.8 |
| Diastolic blood pressure (mmHg) | 76 ± 11.0 |
| Heart rate (beats per minute) | 72 ± 12 |
| Oxygen saturation (%) (n = 89) | 95 (93-97) |
| Referred for, n (%) | |
| Worsening of dyspnea | 47 (47) |
| Chest pain | 22 (22) |
| Palpitations or ECG changes | 11 (11) |
| Elevation of a cardiac biomarker | 5 (5) |
| Cardiac imaging abnormalities | 4 (4) |
| Episode of decompensated heart failure | 4 (4) |
| Recent stroke | 4 (4) |
| Pretransplant assessment (kidney/HSCs) | 3 (3) |
| Cardiovascular risk factors, n (%) | |
| Arterial hypertension | 67 (67) |
| Diabetes | 4 (4) |
| Dyslipidemia | 1 (1) |
| Obesity | 7 (7) |
| Obstructive sleep apnea syndrome | 11 (11) |
| Chronic kidney disease∗ | 35 (35) |
| Active smoking | 12 (12) |
| Thromboembolic history (PE/DVT) | 28 (28) |
| Treatment of SCD, n (%) | |
| None | 12 (12) |
| Hydroxyurea | 61 (61) |
| Erythrocytapheresis | 6 (6) |
| Hydroxyurea + erythrocytapheresis | 21 (21) |
| Bloodletting | 1 (1) |
| Biology | |
| Hemoglobin (g/dL) | 8.7 ± 1.5 |
| Leukocytes (G/L) | 7.8 ± 2.5 |
| Platelets (G/L) | 298 ± 128 |
| Potassium (mmol/L) | 4.3 ± 0.5 |
| Creatinine (μmol/L) | 63 (52-104) |
| GFR (based on CKD-EPI formula in mL/min per 1.73 m2) | 102 (86-118) |
| ASAT (IU/L) | 45 (32-60) |
| ALAT (IU/L) | 24 (20-34) |
| LDH (IU/L) | 446 (353-600) |
| Total bilirubin (μmol/L) | 29 (18-47) |
| Free bilirubin (μmol/L) | 20 (12-34) |
| Nt Pro-BNP (ng/L) | 155 (74-452) |
| Troponin T (Hs) (ng/L) | 5 (3-10) |
| Characteristics . | Patients (n = 100) . |
|---|---|
| Demographic and clinical | |
| Age (y) | 46.0 ± 12.5 |
| Male, n (%) | 48 (48) |
| Body mass index (kg/m2) | 24.1 ± 4.3 |
| Systolic blood pressure (mmHg) | 131 ± 17.8 |
| Diastolic blood pressure (mmHg) | 76 ± 11.0 |
| Heart rate (beats per minute) | 72 ± 12 |
| Oxygen saturation (%) (n = 89) | 95 (93-97) |
| Referred for, n (%) | |
| Worsening of dyspnea | 47 (47) |
| Chest pain | 22 (22) |
| Palpitations or ECG changes | 11 (11) |
| Elevation of a cardiac biomarker | 5 (5) |
| Cardiac imaging abnormalities | 4 (4) |
| Episode of decompensated heart failure | 4 (4) |
| Recent stroke | 4 (4) |
| Pretransplant assessment (kidney/HSCs) | 3 (3) |
| Cardiovascular risk factors, n (%) | |
| Arterial hypertension | 67 (67) |
| Diabetes | 4 (4) |
| Dyslipidemia | 1 (1) |
| Obesity | 7 (7) |
| Obstructive sleep apnea syndrome | 11 (11) |
| Chronic kidney disease∗ | 35 (35) |
| Active smoking | 12 (12) |
| Thromboembolic history (PE/DVT) | 28 (28) |
| Treatment of SCD, n (%) | |
| None | 12 (12) |
| Hydroxyurea | 61 (61) |
| Erythrocytapheresis | 6 (6) |
| Hydroxyurea + erythrocytapheresis | 21 (21) |
| Bloodletting | 1 (1) |
| Biology | |
| Hemoglobin (g/dL) | 8.7 ± 1.5 |
| Leukocytes (G/L) | 7.8 ± 2.5 |
| Platelets (G/L) | 298 ± 128 |
| Potassium (mmol/L) | 4.3 ± 0.5 |
| Creatinine (μmol/L) | 63 (52-104) |
| GFR (based on CKD-EPI formula in mL/min per 1.73 m2) | 102 (86-118) |
| ASAT (IU/L) | 45 (32-60) |
| ALAT (IU/L) | 24 (20-34) |
| LDH (IU/L) | 446 (353-600) |
| Total bilirubin (μmol/L) | 29 (18-47) |
| Free bilirubin (μmol/L) | 20 (12-34) |
| Nt Pro-BNP (ng/L) | 155 (74-452) |
| Troponin T (Hs) (ng/L) | 5 (3-10) |
Ordinal data are reported as mean ± standard deviation when they have a normal distribution, or as median (Q1-Q3) when they do not have a normal distribution, and nominal data as absolute value and percentage.
ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; CKD-Epi, Chronic Kidney Disease Epidemiology Collaboration; DVT, deep veinous thrombosis; GFR, glomerular filtration rate; HSCs, hematopoietic stem cells; LDH, lactate dehydrogenase; PE, pulmonary embolism.
GFR < 90 mL/min per 1.73 m2 according to CKD-EPI.